RhumbLine Advisers’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.82M | Buy |
287,401
+6,339
| +2% | +$106K | ﹤0.01% | 1437 |
|
|
2025
Q1 | $4.32M | Buy |
281,062
+2,128
| +0.8% | +$32.7K | ﹤0.01% | 1432 |
|
|
2024
Q4 | $6.15M | Sell |
278,934
-43,150
| -13% | -$951K | 0.01% | 1326 |
|
|
2024
Q3 | $5.8M | Sell |
322,084
-16,571
| -5% | -$299K | 0.01% | 1348 |
|
|
2024
Q2 | $5.5M | Sell |
338,655
-2,396
| -0.7% | -$38.9K | 0.01% | 1347 |
|
|
2024
Q1 | $4.81M | Buy |
341,051
+8,259
| +2% | +$117K | ﹤0.01% | 1439 |
|
|
2023
Q4 | $3.47M | Buy |
332,792
+33,792
| +11% | +$353K | ﹤0.01% | 1625 |
|
|
2023
Q3 | $3.05M | Buy |
299,000
+33,436
| +13% | +$341K | ﹤0.01% | 1629 |
|
|
2023
Q2 | $2M | Buy |
+265,564
| New | +$2M | ﹤0.01% | 1905 |
|
|
2020
Q3 | – | Sell |
-13,870
| Closed | -$171K | – | 3039 |
|
|
2020
Q2 | $171K | Buy |
+13,870
| New | +$171K | ﹤0.01% | 2826 |
|